Journal ArticleDOI
An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder.
Joseph Biederman,Eric Mick,Thomas J. Spencer,Robert Doyle,Gagan Joshi,Paul Hammerness,Megan Kotarski,Megan Aleardi,Janet Wozniak +8 more
Reads0
Chats0
TLDR
Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder and future placebo-controlled, double blind studies are warranted.Abstract:
INTRODUCTION Aripiprazole is a novel second-generation antipsychotic approved for the treatment of bipolar disorder in adults but there is no systematic data available in pediatric bipolar disorder. METHODS This was an 8-week, open-label, prospective study of aripiprazole 9.4+/-4.2 mg/day monotherapy to assess the efficacy and tolerability of this compound in treating pediatric bipolar disorder. Assessments included the Young Mania Rating Scale, Clinical Global Impressions-Improvement scale, and Brief Psychiatric Rating Scale. Adverse events were assessed through spontaneous self-reports, vital signs weight monitoring, and laboratory analysis. RESULTS Fifteen of the 19 bipolar youth (79%) completed the study. Aripiprazole treatment was associated with clinically and statistically significant improvement in mean Young Mania Rating Scale scores (-18.0+/-6.9, P<.0001). With the important exception of two cases of extrapyramidal symptoms that precipitated dropout, aripiprazole was well tolerated with no statistically significant increase in body weight (1.8+/-1.7 kg, P=.2). CONCLUSION Open-label aripiprazole treatment was beneficial in the treatment of mania in youth with bipolar disorder. Future placebo-controlled, double-blind studies are warranted.read more
Citations
More filters
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Lakshmi N. Yatham,Sidney H. Kennedy,Sagar V. Parikh,Ayal Schaffer,Serge Beaulieu,Martin Alda,Claire O'Donovan,Glenda MacQueen,Roger S. McIntyre,Verinder Sharma,Arun V. Ravindran,L. Trevor Young,Roumen Milev,David J. Bond,Benicio N. Frey,Benjamin I. Goldstein,Beny Lafer,Boris Birmaher,Kyooseob Ha,Willem A. Nolen,Michael Berk,Michael Berk +21 more
TL;DR: The Canadian Network for Mood and Anxiety Treatments published guidelines for the management of bipolar disorder in 2005, with updates in 2007 and 2009, and this third update, in conjunction with the International Society for Bipolar Disorders, reviews new evidence and is designed to be used in conjunctionWith the previous publications.
Journal ArticleDOI
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.
Lakshmi N. Yatham,Sidney H. Kennedy,Ayal Schaffer,Sagar V. Parikh,Serge Beaulieu,Claire O'Donovan,Glenda MacQueen,Roger S. McIntyre,Verinder Sharma,Arun V. Ravindran,L. Trevor Young,Allan H. Young,Martin Alda,Roumen Milev,Eduard Vieta,Joseph R. Calabrese,Michael Berk,Kyooseob Ha,Flávio Kapczinski +18 more
TL;DR: New data support the use of quetiapine monotherapy and adjunctive therapy for the Prevention of manic and depressive events, aripiprazole monotherapy for the prevention of manic events, and risperidone long-acting injection monotherapy
Journal ArticleDOI
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.
Randall Owen,Linmarie Sikich,Ronald N. Marcus,Patricia K. Corey-Lisle,George Manos,Robert D. McQuade,William H. Carson,Robert L. Findling +7 more
TL;DR: Aripiprazole demonstrated significantly greater global improvements than placebo, as assessed by the mean CGI-I score from week 1 through week 8; however, clinically significant residual symptoms may still persist for some patients.
Journal ArticleDOI
A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder
Ronald N. Marcus,Randall Owen,Lisa Kamen,George Manos,Robert D. McQuade,William H. Carson,Michael G. Aman +6 more
TL;DR: Aripiprazole was efficacious and generally safe and well tolerated in the treatment of children and adolescents with irritability associated with autistic disorder.
Journal ArticleDOI
A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI.
Andy Wolff,Revan Kumar Joshi,Jörgen Ekström,Doron J. Aframian,Anne Marie Lynge Pedersen,Gordon Proctor,Nagamani Narayana,Alessandro Villa,Ying Wai Sia,Ardita Aliko,Richard McGowan,Alexander Ross Kerr,Siri Beier Jensen,Arjan Vissink,Colin Dawes +14 more
TL;DR: A comprehensive list of medications with documented effects on salivary gland function or symptoms that may assist practitioners in assessing patients who complain of dry mouth while taking medications is compiled.
References
More filters
Journal ArticleDOI
A rating scale for mania: reliability, validity and sensitivity.
TL;DR: The MRS score correlated highly with an independent global rating, and with scores of two other mania rating scales administered concurrently, and also correlated with the number of days of subsequent stay in hospital.
Journal ArticleDOI
Mania-like symptoms suggestive of childhood-onset bipolar disorder in clinically referred children.
Janet Wozniak,Joseph Biederman,Kathleen Kiely,J S Ablon,Stephen V. Faraone,Elizabeth Mundy,Douglas S. Mennin +6 more
TL;DR: The clinical picture of childhood-onset mania is very severe and frequently comorbid with ADHD and other psychiatric disorders, and more work is needed to clarify whether children have ADHD, bipolar disorder, or both.
Journal ArticleDOI
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
Paul E. Keck,Ronald N. Marcus,Stavros Tourkodimitris,Mirza Ali,Amy Liebeskind,A. Saha,Gary G. Ingenito +6 more
TL;DR: Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.
Journal ArticleDOI
Ziprasidone in the Treatment of Acute Bipolar Mania: A Three-Week, Placebo-Controlled, Double-Blind, Randomized Trial
TL;DR: Ziprasidone monotherapy was significantly superior to placebo in reducing symptoms of acute mania in patients with bipolar I disorder.
Journal ArticleDOI
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Mauricio Tohen,Terence A. Ketter,Carlos A. Zarate,Trisha Suppes,Mark A. Frye,Lori L. Altshuler,John Zajecka,Leslie M. Schuh,Richard C. Risser,Eileen Brown,Robert W. Baker +10 more
TL;DR: Over 47 weeks, mean improvement in Young Mania Rating Scale score was significantly greater for the olanzapine group, and median time to symptomatic mania remi...